Relative Bioavailability Comparison of BI 1015550 as the Intended Commercial Formulation (iCF) Versus Trial Formulation 2 and iCF With and Without Food Following Oral Administration in Healthy Subjects (an Open-label, Randomised, Single-dose, Three-way Crossover Trial)
Latest Information Update: 07 Oct 2022
At a glance
- Drugs Nerandomilast (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
Most Recent Events
- 04 Oct 2022 Status changed from active, no longer recruiting to completed.
- 06 Sep 2022 Status changed from recruiting to active, no longer recruiting.
- 23 Aug 2022 Status changed from not yet recruiting to recruiting.